Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Serious adverse events that occur with the administration of iron dextran are due to the high molecular weight preparations. Conclusions that iron sucrose and ferric gluconate are safer than iron dextran may be premature. Published literature comparing safety profiles of available parenteral iron products is reviewed. Administration of iron salts to pre-dialysis patients with chronic kidney disease may not be optimal. We recommend the total dose infusion of low molecular weight iron dextran as an option for iron replacement.
Auerbach
M
M
Auerbach Hematology and Oncology, Baltimore, Maryland 21237, USA. mauerbachmd@aol.com
Al Talib
K
K
D002908:Chronic Disease; D005290:Ferric Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid; D006397:Hematinics / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007263:Infusions, Parenteral; D007505:Iron-Dextran Complex / Q000008:administration & dosage / Q000009:adverse effects*; D007674:Kidney Diseases / Q000188:drug therapy*
D005290:Ferric Compounds; D006397:Hematinics; D007505:Iron-Dextran Complex; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid